Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cns Pharmaceuticals Inc (NQ: CNSP )

0.1512 +0.0051 (+3.49%)
Streaming Delayed Price Updated: 2:29 PM EDT, Sep 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,843,009
Open 0.1474
Bid (Size) 0.1499 (52)
Ask (Size) 0.1525 (2)
Prev. Close 0.1461
Today's Range 0.1405 - 0.1531
52wk Range 0.0955 - 137.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Slated to Present at H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Via ACCESSWIRE

Performance

YTD
-99.75%
-99.75%
1 Month
-6.38%
-6.38%
3 Month
-95.62%
-95.62%
6 Month
-99.30%
-99.30%
1 Year
-99.79%
-99.79%

More News

Read More
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Latest BioMedWire Podcast Episode
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Via Investor Brand Network
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Via ACCESSWIRE
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
Via ACCESSWIRE
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
What's Going On With CNS Pharmaceuticals Stock Tuesday?
Via Benzinga
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Upcoming Virtual Investor CEO Connect Segment
Via Investor Brand Network
Scientists Find Way to Boost Natural Killer Cells Targeting Pediatric Brain Cancer
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Publishes Q2 2024 Results
Via Investor Brand Network
Exposures Product Safety
CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q2 2024
Via InvestorPlace
Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Study Uncovers How Brain Tumors Evolve During Treatment
Via Investor Brand Network
Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Microsoft Office Outage: Microsoft Investigates Applications, Services Issue
Via InvestorPlace
SOUN Stock Alert: SoundHound Expands AI Rollout with Stellantis
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?
Via InvestorPlace
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Inks Exclusive License in ‘Transformational’ Step to Treating GBM
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Dow Jumps 200 Points; Pfizer Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CMO to Present Poster at Upcoming SNO/ASCO CNS Cancer Conference
Via Investor Brand Network
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
Via ACCESSWIRE
Study Uncovers Ancient Egyptian Attempts to Surgically Remove Brain Cancer
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.